# Empirical evaluation of prediction intervals for cancer incidence

- Bjørn Møller
^{1}Email author, - Harald Weedon-Fekjær
^{1}and - Tor Haldorsen
^{1}

**5**:21

https://doi.org/10.1186/1471-2288-5-21

© Møller et al; licensee BioMed Central Ltd. 2005

**Received: **25 February 2005

**Accepted: **10 June 2005

**Published: **10 June 2005

## Abstract

### Background

Prediction intervals can be calculated for predicting cancer incidence on the basis of a statistical model. These intervals include the uncertainty of the parameter estimates and variations in future rates but do not include the uncertainty of assumptions, such as continuation of current trends. In this study we evaluated whether prediction intervals are useful in practice.

### Methods

Rates for the period 1993–97 were predicted from cancer incidence rates in the five Nordic countries for the period 1958–87. In a Poisson regression model, 95% prediction intervals were constructed for 200 combinations of 20 cancer types for males and females in the five countries. The coverage level was calculated as the proportion of the prediction intervals that covered the observed number of cases in 1993–97.

### Results

Overall, 52% (104/200) of the prediction intervals covered the observed numbers. When the prediction intervals were divided into quartiles according to the number of cases in the last observed period, the coverage level was inversely proportional to the frequency (84%, 52%, 46% and 26%). The coverage level varied widely among the five countries, but the difference declined after adjustment for the number of cases in each country.

### Conclusion

The coverage level of prediction intervals strongly depended on the number of cases on which the predictions were based. As the sample size increased, uncertainty about the adequacy of the model dominated, and the coverage level fell far below 95%. Prediction intervals for cancer incidence must therefore be interpreted with caution.

## Background

Prediction of cancer incidence is of great interest for both health authorities and the scientific community [1]. Estimates of the future cancer burden should indicate the appropriate amounts of resources that will be needed for diagnosis, treatment and rehabilitation. Since quantification of future cancer incidence is inherently uncertain [2], some measurement of the uncertainty would be useful. It has been suggested that, similar to the confidence intervals calculated in standard statistical modeling, prediction intervals should be presented with predictions of cancer incidence [3, 4].

When future cancer incidence is predicted in a statistical model, three sources of uncertainty are associated with the predicted numbers. The first is the variance of the parameters estimated in the model; the second is the random variation of the future number of cases; and the third is the adequacy of the model. The last includes the uncertainty in both the mathematical structure of the model and the choice of projected components, such as whether to assume that current trends will continue into the future. The first two sources of variance can be included in a statistical model. Intervals that are based only on the variance of the parameters estimated in the model are called 'confidence intervals', while intervals that also encompass variation in the future number of cases are called 'prediction intervals'.

The third source of uncertainty, variations caused by deviations from the model assumptions, is difficult to formalize. Engeland et al. [5] argued that "The large uncertainties associated with the specification of the models used in the predictions obviate the construction of confidence intervals." One way of investigating the extent of the uncertainty in specification of a model is to calculate prediction intervals from historical data and then calculate the proportion of those intervals that actually cover the observed number of cancer cases. If the proportion is close to the nominal level, e.g. 95 %, the prediction intervals could be taken to give a fair description of the range of likely values to be expected. A low proportion would indicate that there was great uncertainty in the model assumptions, and that prediction intervals should be interpreted with caution. The aim of this study was to evaluate the extent to which prediction intervals derived from incidence rates can be expected to cover the actual numbers observed 10 years later.

## Methods

### Material

The material consisted of new cases of cancer reported to the cancer registries of Denmark, Finland, Iceland, Norway and Sweden between 1958 and 1997, and population figures covering the same calendar period from the central statistical offices in these countries. Sweden has the largest population, with 8.9 million inhabitants, followed by Denmark, Finland, Norway and Iceland with 5.3, 5.2, 4.5 and 0.3 million, respectively. The Nordic cancer registries receive reports from physicians, hospitals, pathological and cytological laboratories and (except in Sweden) death certificates [6]. Compulsory reporting and information from multiple sources ensure almost 100% completeness of all the cancer registries [7].

Proportions of observed numbers of cases in 1993–97 covered by prediction intervals based on trends up to 1987, by site, sex, country and frequency*.

Number of intervals | Coverage number (%) | P-value for difference | |
---|---|---|---|

Site | 0.54 | ||

Lip | 5 | 2 (40) | |

Tongue, oral cavity and pharynx | 10 | 5 (50) | |

Oesophagus | 10 | 5 (50) | |

Stomach | 10 | 5 (50) | |

Colon | 10 | 7 (70) | |

Rectum | 10 | 5 (50) | |

Pancreas | 10 | 6 (60) | |

Larynx | 5 | 3 (60) | |

Lung | 10 | 4 (40) | |

Breast | 5 | 2 (40) | |

Cervix uteri | 5 | 2 (40) | |

Corpus uteri | 5 | 2 (40) | |

Ovary | 5 | 1 (20) | |

Prostate | 5 | 2 (40) | |

Testis | 5 | 4 (80) | |

Kidney | 10 | 7 (70) | |

Urinary bladder | 10 | 5 (50) | |

Melanoma of the skin | 10 | 3 (30) | |

Thyroid | 10 | 7 (70) | |

Non-Hodgkin lymphomas | 10 | 4 (40) | |

Hodgkin disease | 10 | 9 (90) | |

Multiple myeloma | 10 | 4 (40) | |

Acute leukaemia | 10 | 7 (70) | |

Other sites | 10 | 3 (30) | |

Sex | 0.67 | ||

Male | 100 | 50 (50) | |

Female | 100 | 54 (54) | |

Country | <0.001 | ||

Denmark | 40 | 18 (45) | |

Finland | 40 | 21 (53) | |

Iceland | 40 | 35 (88) | |

Norway | 40 | 20 (50) | |

Sweden | 40 | 10 (25) | |

Frequency | <0.001 | ||

≤ 70 per year | 50 | 42 (84) | |

> 70 and ≤ 230 per year | 50 | 26 (52) | |

> 230 and ≤ 555 per year | 50 | 23 (46) | |

> 555 per year | 50 | 13 (26) |

The data were tabulated in five-year age groups (0–4, 5–9, ..., 80–84, ≥85) and five-year calendar periods (1958–62, 1963–67, ..., 1993–97). Since there were 20 types of cancers for each sex and five countries in the study, we had 200 different combinations for which to make predictions.

### Statistical model

The age-period-cohort (APC) model [8] has been widely used for predicting cancer incidence and mortality [9–13]. This Poisson regression model is based on tables with five-year age groups and five-year calendar periods. Birth cohorts were constructed synthetically by subtracting age from period. The model can be written as

*R*
_{
ap
}= exp(*A*
_{
a
}+ *D*·*p* + *P*
_{
p
}+ *C*
_{
c
}),

where *R*
_{
ap
}is the incidence rate in age group *a* in calendar period *p*, *D* is the common drift parameter [14], *A*
_{
a
}is the age component for age group *a*, *P*
_{
p
}is the non-linear period component of period *p* and *C*
_{
c
}is the non-linear cohort component of cohort *c*, *c* = *p* - *a*. We used a slightly modified model [5], substituting a power link for the log link:

*R*
_{
ap
}= (*A*
_{
a
}+ *D*·*p* + *P*
_{
p
}+ *C*
_{
c
})^{5},

in order to level off the exponential growth in the multiplicative model. An empirical study of these two models showed that the power model gave predictions that were closer to the observed rates [2]. For some cancer sites for which there were only a few cases in Iceland, a model without the cohort component was used; see Engeland et al. [5] for details and on the lower limits of the age groups included for each site in all the countries.

To ensure a reasonable fit of each data set to the model, the number of five-year periods on which the predictions should be based on was chosen. First, a model including the last six 5-year periods (1958–1987) was fitted. If the model was rejected by a test for goodness-of-fit (5% level), a model including the last five periods was fitted. If this model was also rejected, only the last four periods were used.

Future non-linear effects of cohort and period were assumed to be equal to the last estimated effect in the model, and predictions were made by projecting the drift. Numbers of cancer cases were predicted by multiplying the predicted rates by the person-years at risk in a given age group and time period.

### Prediction intervals, coverage level and discrepancy ratio

In an article on the precision of cancer incidence predictions, Hakulinen and Dyba [3] derived prediction intervals for Poisson distributed variables. Following their paper, let
, where *a* is the age group, *f* is the future calendar period for which predictions are to be made (*f* = 8 which corresponds to the period 1993–97), *R*
_{
af
}is the incidence rate in age group *a* in period *f*, and *k*
_{
af
}and *n*
_{
af
}are the corresponding number of cases and person-years, respectively. Further, let the expected number of cases, E(*k*
_{
af
}), be defined as *λ*
_{
af
}= *n*
_{
af
}(*A*
_{
a
}+ *D*·*P* + *P*
_{
f
}+ *C*
_{
c
})^{5}, and let
and
. The variance of the future number of cases, var (*k*
_{
f
}), can be written as var (*k*
_{
f
}) = var (
) + *σ*
^{2} E(
). The first component, var (
), reflects the uncertainty in estimating the parameters in the model. The second component, *σ*
^{2} E(
), reflects the random variation of the future number of cases for a Poisson-distributed variable, allowing for extra-Poisson variation, i.e., *σ*
^{2} measures the degree of over-dispersion.

An estimator for the variance of the future number of cases can be found by using Taylor series expansion of non-linear functions (see formulas in the appendix). A 95% prediction interval for the future number of cancer cases, *k*
_{
f
}, can then be calculated from an assumption of normality:

where *k*
_{
f
}was estimated by
.

On the basis of up to six 5-year periods between 1958 and 1987, prediction intervals for the numbers of cases in the period 1993–97 were calculated for all 200 combinations of 20 sites for each sex in each of the five countries. The coverage level was defined as the proportion of the prediction intervals that covered the observed number of cases in 1993–97.

The coverage level only indicates whether the observed number of cases was inside the prediction interval or not. Additional information can be gained by looking at how far outside of the interval the observations fall. Discrepancy ratio was defined as the absolute distance between observed and predicted number of cases, measured in half prediction interval widths:

*k*

_{ f }are the predicted and observed number of cases, respectively, and is the distance between predicted number of cases and the limit of the prediction interval. Figure 1 illustrates the discrepancy ratio. When the discrepancy ratio is larger than 1, it measures how much wider the prediction interval had to be to cover the observed number of cases. In Figure 1, the observed number of cases is about twice as far from the predicted number compared to the lower limit of the prediction interval, giving a discrepancy ratio of 2.

Fisher's exact test was used to evaluate differences between sites, countries and quartiles of number of cases. A binomial regression model was used to study the effect of country and frequency simultaneously.

## Results

Prediction intervals were calculated from data up to 1987 for the 200 combinations of sex, site and country. After observing the number of cases 10 years later, in the period 1993–97, 104 (52%) of the observed numbers were covered by the prediction intervals. Coverage levels for specific sites varied from 20% to 90%, but only five or ten intervals were calculated for each site and the difference between the sites was not statistically significant (Table 1).

The coverage levels for the five Nordic countries varied widely. For the country with the smallest population, Iceland, the coverage level was 88%, which is relatively close to the nominal level of 95%. The levels for Denmark, Finland and Norway were around 50 %, while that for Sweden, the most populous country, was only 25%. When the 200 different predictions were ranked according to the annual number of cases in the period 1983–87 (frequency), the cut-offs for the four quartiles were 70, 230 and 555. Subdividing the predictions according to these quartiles, the coverage level decreased markedly with the annual number of cases, being 84% for the first quartile and 52%, 46% and 26% for the next three, respectively (Table 1).

Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for covering the observed number of cases in the period 1993–97 with the prediction intervals calculated from trends up to 1987.

Crude | Adjusted* | |||||
---|---|---|---|---|---|---|

OR | 95 % CI | P-value | OR | 95 % CI | P-value | |

Country | < 0.001 | 0.39 | ||||

Denmark | 1.00 | Reference | 1.00 | Reference | ||

Finland | 1.35 | 0.56 – 3.2 | 1.18 | 0.47 – 2.9 | ||

Iceland | 8.54 | 2.8 – 26.3 | 1.72 | 0.39 – 7.6 | ||

Norway | 1.22 | 0.51 – 2.9 | 1.08 | 0.43 – 2.7 | ||

Sweden | 0.41 | 0.16 – 1.1 | 0.49 | 0.18 – 1.3 | ||

Log(frequency) | 0.52 | 0.41 – 0.66 | < 0.001 | 0.60 | 0.44 – 0.83 | 0.02 |

## Discussion

A statistical model is only a simplification of true underlying associations between variables. The finding that the coverage level is inversely proportional to the sample size can be explained by considering the difference between the modeled (simplified) and true (complex) relationship between the cancer rate and the explanatory variables age, period and cohort. When the sample size increases, deviations between the modeled and true relationship will dominate, and non-overage will become a problem. It is useful to distinguish between calculations of prediction intervals for values within the observed range of values of the explanatory variables (interpolation), and outside the range (extrapolation). The non-coverage problem is even larger for extrapolations, because they also relay on the assumption of continuation of current trends. Another difference between interpolation and extrapolation is that when the sample size increases, the possibility to improve the model increases. This would then reduce the non-coverage problem for interpolations, by reducing the distance between the true and the modeled relationship between the variables. Extrapolations, on the other hand, consist of making predictions for values of the covariates outside the range of observed values. Thus, we have to make assumptions that cannot be evaluated from the observed data and the problem with non-coverage for extrapolations are not necessarily reduced by improvements in the model.

It could be argued that a low coverage level indicates that the model is not appropriate, rather than that calculation of predication intervals is per se misleading. With the possible exception of tobacco and lung cancer, few associations are strong enough to be modelled directly. Instead, we used calendar period and birth cohort as proxy variables for changes in underlying risk factors in the model. Møller et al. [2] found that the method used in this study performed fairly well in comparison with other methods currently in use for predicting cancer incidence, and that all the methods evaluated missed the observed number of cases by 10–15% on average for 10 year predictions. Prediction methods could therefore be improved to increase the overall coverage level, although it would be unreasonable to expect that the correct model, or close to it, could be specified for all cancer sites. As long as predictions are based on some type of extrapolation from a statistical model, the coverage level will generally decrease as a function of sample size. The problem is that at the time when the prediction intervals are calculated, the appropriateness of the model with respect to extrapolation into the future usually cannot be evaluated. Prediction intervals can thus be misleading, if they are interpreted as the range of likely values for the number of cases to be expected.

The number of cases from which the predictions for the different cancer sites were made varied widely. Cancers at some sites are very common, like those of the prostate, lung and breast, while others occur less frequently. Because the coverage levels vary with frequency, we would also have expected them to vary by site. The differences were not, however, statistically significant, probably because of the small number of prediction intervals calculated for each site.

A relatively large sample size was associated with a narrow prediction interval, as seen for lung cancer among women in Denmark (Figure 3). The prediction intervals are based on asymptotic theory, which can result in underestimates of variance. Bootstrapping is a suitable method for investigating this problem [16]. We constructed a 95% prediction interval by bootstrapping the data for lung cancer among women in Denmark, assuming that each cell followed a binomial distribution in which the incidence rate and the number of person-years at risk were used as probability of success and number of trials, respectively. We re-sampled the data 1000 times, calculating the predicted world-standardized incidence rate each time. The 95% bootstrap interval, calculated by selecting the 2.5 and 97.5 percentiles of the 1000 predictions, was 32.7 – 36.7, which is fairly close to the asymptotic interval of 32.6–36.8. This indicates that the asymptotic intervals calculated in this study describe the uncertainty in the predicted number of cases well, given a correctly specified model.

Population forecasts are needed for predicting the number of cancer cases. In this paper, we assumed that these numbers were known, but in reality they constitute a separate source of uncertainty. Population forecasts are themselves extrapolations, relying on assumptions about future migration patterns, birth rates and death rates. If our projections for 1993–97 had been calculated from population forecasts in 1987, the coverage levels would probably have been even lower.

Most of the differences in coverage level among the five countries disappeared when the number of cases was controlled for. The remaining difference was not significant, but the probability of covering the rates with prediction intervals for Sweden continued to be lower after adjustment of sample size. Møller et al. [2] showed that the predictions for Sweden were more different from the observed number of cases in 1993–97 than those in the other countries, measured as the median of the absolute value of the relative difference between the predicted and observed numbers of cases. This explains the lower coverage level for Sweden, and indicates that the trends current in 1987 continued to a lesser extent in Sweden than in the other countries.

Engeland and co-workers [5] were reluctant to include prediction intervals with their predictions of cancer incidence in the Nordic countries. A similar view was expressed both with regard to an update of predictions for the Nordic countries [17], and to a prediction of cancer incidence in New South Wales, Australia [18]. There are, however, some instances where prediction intervals can be of value. In cancer surveillance, inclusion of prediction intervals in a routine comparison of the latest observed rates with rates predicted from previous trends, can help to identify changes in the rates beyond random variation. The potential reasons for any discrepancy between the observed and predicted rates can then be studied, including changes in risk factors, diagnostic methods or interventions such as screening programs. In Finland, predicted values with prediction intervals for 1980 were calculated based on rates up to 1968 and compared to observed number of cases in 1980 [19]. Of 33 prediction intervals, 22 (67%) covered the observed values, and the authors discussed possible reasons for those cancers where the prediction intervals failed to cover the observed number of cases. Prediction intervals can also be used to identify highly uncertain predictions. For instance, 26 male cancer cases of the lip were predicted in Iceland in the period 1993–97, and the 95 % prediction interval was 6–46 cases.

## Conclusion

We do not recommend use of prediction intervals when the predictions are used for administrative purposes, like planning appropriate amounts of resources for diagnosis, treatment and rehabilitation, as the intervals can give a false impression of the precision of the predictions. When predictions are based on larger numbers of cases, the uncertainty in estimating the parameters of the model and the random variation of the future rates are decreased. Even relatively minor deviations in the assumptions can then result in observed rates in the future that are outside the range of likely values indicated by the prediction interval.

## Appendix

A 95 % prediction interval for the future number of cancer cases, *k*
_{
f
}, can be calculated on the basis of an assumption of normality:
were *k*
_{
f
}can be estimated by
. The variance of *k*
_{
f
}can be written
, and
and
can be estimated by Taylor series expansion of non-linear functions:

Further, the parameter for over-dispersion, *σ*
^{2}, can be estimated from the ratio between the residual deviance of the model and the corresponding number of degrees of freedom [20], and
can be estimated by
. We used the statistical package R in the calculations, and the variances and covariances of the estimates of the parameters in the model were found in the covariance matrix of the glm-object.

## Declarations

### Acknowledgements

The authors would like to thank Petter Laake for valuable comments on the article. The project is supported by the Nordic Cancer Union.

## Authors’ Affiliations

## References

- Hakulinen T, Hakama M: Predictions of epidemiology and the evaluation of cancer control measures and the setting of policy priorities. Soc Sci Med. 1991, 33: 1379-1383. 10.1016/0277-9536(91)90282-H.View ArticlePubMedGoogle Scholar
- Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, Haldorsen T: Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003, 22: 2751-2766. 10.1002/sim.1481.View ArticlePubMedGoogle Scholar
- Hakulinen T, Dyba T: Precision of incidence predictions based on Poisson distributed observations. Stat Med. 1994, 13: 1513-1523.View ArticlePubMedGoogle Scholar
- Dyba T: Precision of cancer incidence predictions based on Poisson distributed observations. Phd thesis. 2000, Finnish statistical societyGoogle Scholar
- Engeland A, Haldorsen T, Tretli S, Hakulinen T, Hörte T, Luostarinen T, Magnus K, Schou G, Sigvaldason H, Storm HH, Tulinius H, Vaittinen P: Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries. APMIS. 1993, 1-124. Suppl 38Google Scholar
- ANCR. Survey of Nordic Cancer Registries. [http://ncu.cancer.dk/ancr/survey.asp]
- Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H: Trends in cancer incidence in the Nordic countries. A collaborative study of the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand. 1986, 1-151. Suppl 288Google Scholar
- Holford TR: The estimation of age, period and cohort effects for vital rates. Biometrics. 1983, 39: 311-324.View ArticlePubMedGoogle Scholar
- Osmond C: Using age, period and cohort models to estimate future mortality rates. Int J Epidemiol. 1985, 14: 124-129.View ArticlePubMedGoogle Scholar
- Negri E, La Vecchia C, Levi F, Randriamiharisoa A, Decarli A, Boyle P: The application of age, period and cohort models to predict Swiss cancer mortality. J Cancer Res Clin Oncol. 1990, 116: 207-214. 10.1007/BF01612679.View ArticlePubMedGoogle Scholar
- Kubík A, Pleško I, Reissigová J: Prediction of lung cancer mortality in four Central European countries, 1990–2009. Neoplasma. 1998, 45: 60-67.PubMedGoogle Scholar
- Kiemeney L, Van Berkel H, Witjes JA, Sonke GS, Debruyne FM, Straatman H: Kidney cancer mortality in The Netherlands, 1950–94: prediction of a decreasing trend. J Epidemiol Biostat. 1999, 4: 303-311.PubMedGoogle Scholar
- Sharp L, Black RJ, Muir CS, Gemmell I, Finlayson AR, Harkness EF: Will the Scottish Cancer Target for the year 2000 be met? The use of cancer registration and death records to predict future cancer incidence and mortality in Scotland. Br J Cancer. 1996, 73: 1115-1121.View ArticlePubMedPubMed CentralGoogle Scholar
- Clayton D, Schifflers E: Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med. 1987, 6: 469-481.View ArticlePubMedGoogle Scholar
- Breslow NE, Day NE: Statistical methods in cancer research. The design and analysis of cohort studies. 1987, Lyon: IARC press, II:Google Scholar
- Efron B, Tibshirani RJ: An introduction to the bootstrap. 1993, New York: Chapmann & HallView ArticleGoogle Scholar
- Møller B, Fekjær H, Hakulinen T, Tryggvadóttir L, Storm HH, Talbäck M, Haldorsen T: Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev. 2002, S1-S96. Suppl 1Google Scholar
- Coory M, Armstrong BK: Cancer Incidence Projections for Area and Rural Health Services in New South Wales. 1998, Sidney: NSW Cancer CouncilGoogle Scholar
- Hakulinen T, Teppo L, Saxén E: Do the predictions for cancer incidence come true? Experience from Finland. Cancer. 1986, 57: 2454-2458.View ArticlePubMedGoogle Scholar
- McCullagh P, Nelder JA: Generalized Linear Models. 1989, London: Chapman & Hall, SecondView ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/5/21/prepub

### Pre-publication history

## Copyright

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.